Home Equities Score Annovis Bio, Inc. (ANVS) Stock Skyrockets Following Success of Clinical Trial and...

Annovis Bio, Inc. (ANVS) Stock Skyrockets Following Success of Clinical Trial and Subsequent Public Offering

Annovis Bio, Inc. (ANVS) stock prices skyrocketed by a staggering 127.27% as of the market closing on May 21st, 2021, bringing the price per share up to an even USD$60.00.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

ANVS401 Study

The company announced on May 21st, 2021 the success of its double-blind placebo-controlled study in the treatment of Alzheimer’s Disease. Patients treated with ANVS401 for a period of 25 days exhibited statistically significant cognitive improvement, according to the study. The cognitive improvement was measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

Read More

Success of Study

The 11-part test is the standard in the measurement of impaired cognition in clinical trials for Alzheimer’s Diseases. The cohort that received ANVS401 showed a statistically significant and highly promising 30% improvement. The same cohort exhibited an improvement of 22% compared with the placebo group.

Pristine Safety Data

Prior safety data had established the safety profile of the ANVS401 drug, with interim analysis reports further consolidating the treatment as safe. The interim analysis showed ANVS401 to be safe at a dosage level and frequency of 80mg once a day in humans, with no adverse events that could have been ascribed to the drug treatment.

Trajectory of ANVS401

Following this success, ANVS expects full study data by the end of the Summer of 2021, including a dose range analysis in a cohort of 40 Parkinson’s patients. After the forecasted success of the Phase 2a trial, ANVS hopes to request a meeting with the U.S. FDA wherein the company will present the results of the trial and its chronic toxicology study in animals. Assuming the company’s trajectory stays on track, it forecasts progression into late-stage studies by later in the fiscal year 2021.

Scope of ANVS401

The company had previously reported positive results in a study involving Parkinson’s disease patients, with ANVS401 proving to be effective in the treatment of both diseases. The study that achieved these results had a cohort of 14 patients with Alzheimer’s Diseases and Parkinson’s Disease each. The efficacy observed in both patient cohorts supports ANVS’s hypothesis that the impairment of axonal transport affects nerve cells in the same way in both diseases. With more than 6 million Americans living with Alzheimer’s, the number is projected to surge to 13 million by 2050.

ANVS Public Offering

May 23rd saw the company announce the pricing of its previously disclosed public offering of shares of its common stock. ANVS will offer up to 1 million shares with a price of USD$50.00 per share. The offering is expected to close on May 26th, 2021, with gross proceeds in the amount of USD$50 million being generated before the deduction of costs related to the offering. The company hopes to use the generated funds to facilitate the completion of the planned Phase 3 clinical trial for ANVS401.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Future Outlook for ANVS

With such resounding success and a broadened scope for ANVS401, ANVS is poised to capitalize on developments in the commercialization of the treatment. Soon to be armed with a solid liquidity position owing to their ongoing public offering, the company expects to reward its investors with significant and sustained increases in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Adial Pharmaceuticals Inc. (ADIL) stock plunged during pre-market trading. Here’s to know why?

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) stock gained by 9.06% at last close while the ADIL share price fell by 6.07% in the pre-market trading...

Why AbCellera Biologics Inc. (ABCL) stock faced negativity on Tuesday?

AbCellera Biologics Inc. (ABCL) shares lost 2.13% in after-hours on Tuesday, June 22, 2021, and closed the day at $21.60 per share. Earlier, ABCL's...

Biocept Inc. (BIOC) stock surged during current market trading. Why is it so?

Biocept Inc. (NASDAQ: BIOC) stock gained by 3.13% in the current market trading. Biocept creates and sells molecular diagnostic tests that offer doctors with...

Comstock Mining Inc. (LODE) stock soar during pre-market trading. What’s happening?

Comstock Mining Inc. (NASDAQ: LODE) stock gained by 1.14% at last close while the LODE stock price surged by 3.10% in the pre-market trading...

Why MediciNova Inc (MNOV) stock facing negativity since Monday’s after-hours?

MediciNova Inc. (MNOV) shares lost 5.71% in after-hours on Monday, June 21, 2021, and the plummeting continues in the pre-market session on Tuesday as...

Tiziana Life Sciences Inc. (TLSA) stock surged during pre-market. Let’s see why?

Tiziana Life Sciences Inc. (NASDAQ: TLSA) stock declined by 2.54% at last close however the TLSA stock price depicts a rise of 8.26% during...

Adial Pharmaceuticals Inc. (ADIL) stock plunged during pre-market trading. Here’s to know why?

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) stock gained by 9.06% at last close while the ADIL share price fell by 6.07% in the pre-market trading...

Histogen Inc. (HSTO) stock plunged during pre-market trading. What’s driving it low?

Histogen Inc. (NASDAQ: HSTO) stock gained by 16.16% at last close whereas the HSTO stock price declines by 2.73% in the pre-market trading. Histogen...

Related News

Tiziana Life Sciences Inc. (TLSA) stock surged during pre-market. Let’s see why?

Tiziana Life Sciences Inc. (NASDAQ: TLSA) stock declined by 2.54% at last close however the TLSA stock price depicts a rise of 8.26% during...

Pyxis Tankers Inc. (PXS) stock fell during pre-market trading. Why so?

Pyxis Tankers Inc. (NASDAQ: PXS) stock declined by 0.06% at the last close while the PXS stock price plunged by 6.15% in the pre-market...

Globalstar Inc. (NASDAQ: GSAT) stock surged during after-hour session. Here’s the update:

Globalstar Inc. (NASDAQ: GSAT) stock gained by 23.18% at last close while the GSAT stock price rises by 4.3% in the after-hours session. Globalstar...

Millendo Therapeutics Inc. (MLND) stock plunged during after-hour session. Here’s to know why?

Millendo Therapeutics Inc. (NASDAQ: MLND) stock gained by 3.76% at the last close while the MLND stock price declines by 13.04% in the after-hours...

Bio-Path Holdings Inc. (BPTH) stock gains during current market trading. Here’s to know why?

Bio-Path Holdings Inc. (NASDAQ: BPTH) stock surged by 8.76% in the current market trading. Bio-Path is a biotech firm working on DNAbilize, a new...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

7542

GIFT

Download free eBook for 

7 GROWTH  STOCKS FOR 2021

WAIT 
WE HAVE GIFT FOR YOU

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam